Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Allovir Inc (ALVR)

Allovir Inc (ALVR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,534
  • Shares Outstanding, K 115,537
  • Annual Sales, $ 0 K
  • Annual Income, $ -190,420 K
  • EBIT $ -90 M
  • EBITDA $ -89 M
  • 60-Month Beta 0.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.80
  • Most Recent Earnings $-0.04 on 11/12/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 178.47%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +188,590.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5153 +6.71%
on 11/19/24
1.0500 -47.63%
on 11/04/24
-0.2277 (-29.28%)
since 10/22/24
3-Month
0.5153 +6.71%
on 11/19/24
1.0500 -47.63%
on 11/04/24
-0.2154 (-28.15%)
since 08/22/24
52-Week
0.5153 +6.71%
on 11/19/24
2.4850 -77.87%
on 12/14/23
-0.9701 (-63.82%)
since 11/22/23

Most Recent Stories

More News
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

ALVR : 0.5499 (-3.53%)
Why AlloVir Stock Dropped Today

AlloVir briefly plunged amid concerns over selling pressure related to a recent lock-up agreement expiration.

ALVR : 0.5499 (-3.53%)
MarketBeat Week in Review – 7/10 - 7/14

As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week

ENPH : 66.29 (+4.28%)
ACCD : 3.70 (-0.27%)
PEP : 162.00 (+1.04%)
BYND : 4.89 (-2.40%)
ARKK : 56.21 (+2.63%)
PLTR : 64.35 (+4.87%)
BABA : 83.13 (-2.86%)
NVDA : 141.95 (-3.22%)
AVGO : 164.23 (+0.18%)
GILD : 90.19 (+0.48%)
ALVR : 0.5499 (-3.53%)
RCUS : 14.70 (+2.94%)
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

GILD : 90.19 (+0.48%)
AMGN : 294.53 (+1.60%)
BMY : 58.87 (+1.10%)
NVS : 104.28 (+0.41%)
BGNE : 190.51 (-2.08%)
JSPR : 22.05 (+0.96%)
VIGL : 3.19 (+6.33%)
ALVR : 0.5499 (-3.53%)
RCUS : 14.70 (+2.94%)
FLACU : 9.50 (+2.48%)
Why Shares of AlloVir Plummeted This Week

The clinical-stage biotech's shares fell after the company announced a stock sale.

ALVR : 0.5499 (-3.53%)
Stocks Slip Before the Open as Powell’s Hawkish Testimony Weighs on Sentiment, BoE Decision in Focus

September S&P 500 futures (ESU23) are down -0.19%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.29% this morning after three major U.S. benchmark indices ended the regular session lower...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
TSLA : 352.56 (+3.80%)
INTC : 24.50 (+0.25%)
AMD : 138.35 (+0.63%)
QCOM : 156.79 (+0.86%)
FDX : 299.97 (+1.63%)
DLTR : 66.40 (+0.97%)
ELUXB.S.DX : 80.620 (+1.43%)
SESG.P.DX : 3.358 (+1.39%)
ROOT : 109.23 (-0.16%)
AAOI : 37.99 (+7.01%)
Why Shares of AlloVir Jumped This Week

The company's lead therapy fared well in preventing infections for kidney transplant patients.

^RISEBTC : 0.000058 (-23.68%)
ALVR : 0.5499 (-3.53%)
AlloVir Reports First Quarter 2023 Financial Results

AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the first quarter ended March 31, 2023. The company shared progress across its...

ALVR : 0.5499 (-3.53%)
AlloVir to Present at the BofA Securities 2023 Health Care Conference

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, announced today that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the...

ALVR : 0.5499 (-3.53%)
AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the presentation of positive long-term, follow-up data from the Phase 2 study of posoleucel...

ALVR : 0.5499 (-3.53%)

Business Summary

AlloVir, Inc. is a late clinical-stage cell therapy company which focus on restoring natural immunity against life-threatening viral diseases. AlloVir, Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 0.6551
2nd Resistance Point 0.6274
1st Resistance Point 0.5886
Last Price 0.5499
1st Support Level 0.5221
2nd Support Level 0.4944
3rd Support Level 0.4556

See More

52-Week High 2.4850
Fibonacci 61.8% 1.7326
Fibonacci 50% 1.5001
Fibonacci 38.2% 1.2677
Last Price 0.5499
52-Week Low 0.5153

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar